Table 2.
Cumulative incidence of primary outcome and individual outcomes for MI and stroke in patients with metastatic CRPC treated with ADT and abiraterone or enzalutamide from MarketScan database from January 2013 to September 2018
| Abiraterone (n = 4017) | Enzalutamide (n = 2277) | Total (N = 6294) | P valuea | |
|---|---|---|---|---|
| Primary outcomeb | 255 (6.3%) | 116 (5.1%) | 371 (5.9%) | 0.042 |
| MI | 124 (3.1%) | 67 (2.9%) | 191 (3.0%) | 0.748 |
| Stroke | 142 (3.5%) | 57 (2.5%) | 199 (3.2%) | 0.025 |
ADT, androgen deprivation therapy; CRPC, castrate-resistant prostate cancer; MI, myocardial infarction; SD, standard deviation.
a
Statistical testing—numeric variables tested with analysis of variance and categorical variables tested with chi-square.
b
Primary outcome is composite outcomes of MI and stroke.